4D Molecular Therapeutics(FDMT)
$12.23+0.12 (+0.95%)
FDMT
4D Molecular Therapeutics ownership
$12.23
At close:+0.12 (+0.95%)
Want to see FDMT full AI Analyst Report?
4D Molecular Therapeutics (FDMT) Ownership - Who Owns 4D Molecular Therapeutics?
534 Followers
4D Molecular Therapeutics (FDMT) Ownership Overview
- 1.64% Insiders
- 14.21% Mutual Funds
- 10.84% Other Institutional Investors
- 16.52% ETFs
- 56.80% Public Companies and Individual Investors
The ownership structure of 4D Molecular Therapeutics (FDMT) stock is a mix of institutional, retail, and individual investors. Approximately 41.56% of the company’s stock is owned by Institutional Investors, 1.64% is owned by Insiders, and 56.80% is owned by Public Companies and Individual Investors.
The ownership structure of 4D Molecular Therapeutics (FDMT) stock is a mix of institutional, retail, and individual investors. Approximately 41.56% of the company’s stock is owned by Institutional Investors, 1.64% is owned by Insiders, and 56.80% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jun 24, 2026 | Scott Bizily | $117,720 | |
| Dec 18, 2025 | Scott Bizily | $17,822 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Jun 30, 2026 | Graham Capital Management, L.p. | $159,640 | |
| Jun 30, 2026 | Fisher Asset Management Llc | $874,488 | |
| Jun 30, 2026 | $60,462,585 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Peter Kolchinsky | 5,049,779 | Institution | 9.14% | 61,758,797 |
| BlackRock, Inc. | 4,724,904 | Institution | 8.55% | 57,785,576 |
| Vanguard | 2,627,663 | Institution | 4.76% | 32,136,318 |
| Ishares | 2,325,558 | Institution | 4.21% | 28,441,574 |
| Vanguard Index Funds | 2,049,012 | Institution | 3.71% | 25,059,417 |
| Spdr | 1,651,765 | Institution | 2.99% | 20,201,086 |
| Janus Investment Fund | 788,444 | Institution | 1.43% | 9,642,670 |
| Xtrackers | 739,927 | Institution | 1.34% | 9,049,307 |
| David Kirn | 709,153 | Insider | 1.28% | 8,672,941 |
| T. Rowe Price Small-cap Stock Fund, Inc. | 681,919 | Institution | 1.23% | 8,339,869 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 2,049,012 | Institution | 3.71% | 25,059,417 |
| Janus Investment Fund | 788,444 | Institution | 1.43% | 9,642,670 |
| T. Rowe Price Small-cap Stock Fund, Inc. | 681,919 | Institution | 1.23% | 8,339,869 |
| Fidelity Salem Street Trust | 571,734 | Institution | 1.03% | 6,992,307 |
| Tiaa-cref Funds | 564,837 | Institution | 1.02% | 6,907,957 |
| T. Rowe Price Small-cap Value Fund, Inc. | 455,274 | Institution | 0.82% | 5,568,001 |
| Fidelity Concord Street Trust | 376,588 | Institution | 0.68% | 4,605,671 |
| T. Rowe Price Equity Funds, Inc. | 368,160 | Institution | 0.67% | 4,502,597 |
| Dfa Investment Dimensions Group Inc | 323,090 | Institution | 0.58% | 3,951,391 |
| Blackrock Funds | 319,756 | Institution | 0.58% | 3,910,616 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Total Stock Market ETF, VTI ETF | 1,588,533 | Institution | 2.88% | 22,731,907 |
| SPDR S&P BIOTECH ETF, XBI ETF | 1,220,516 | Institution | 2.21% | 15,854,503 |
| iShares Russell 2000 ETF, IWM ETF | 1,175,968 | Institution | 2.13% | 14,246,852 |
| Vanguard Extended Market ETF, VXF ETF | 502,016 | Institution | 0.91% | 7,183,849 |
| iShares Russell 2000 Value ETF, IWN ETF | 426,704 | Institution | 0.77% | 5,169,519 |
| iShares Biotechnology ETF, IBB ETF | 386,456 | Institution | 0.70% | 4,681,914 |
| Dimensional U.S. Small Cap ETF, DFAS ETF | 301,332 | Institution | 0.55% | 3,914,303 |
| SPDR S&P Kensho New Economies Composite ETF, KOMP ETF | 283,791 | Institution | 0.51% | 3,686,445 |
| Vanguard Russell 2000 ETF, VTWO ETF | 266,740 | Institution | 0.48% | 3,817,049 |
| Fidelity Enhanced Small Cap ETF, FESM ETF | 233,095 | Institution | 0.42% | 3,027,904 |
FAQ
Who Owns 4D Molecular Therapeutics (FDMT)?
According to the latest TipRanks data, approximately 41.56% of the company's stock is held by institutional investors, 1.64% is held by insiders, and 56.80% is held by public companies and individual investors.
What percentage of 4D Molecular Therapeutics (FDMT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 41.56% of 4D Molecular Therapeutics (FDMT) stock is held by institutional investors: 14.21% by mutual funds, 16.52% by ETFs and 10.84% by other institutional investors.
What percentage of 4D Molecular Therapeutics (FDMT) stock is held by retail investors?
According to the latest TipRanks data, approximately 56.80% of 4D Molecular Therapeutics (FDMT) stock is held by public companies and individual investors.
Who owns the most shares of 4D Molecular Therapeutics (FDMT)?
Peter Kolchinsky owns the most shares of 4D Molecular Therapeutics (FDMT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

